Goetzinger Katherine R, Odibo Anthony O
Department of Obstetrics and Gynecology, Washington University, St. Louis, MO, USA.
Prenat Diagn. 2014 Jul;34(7):635-41. doi: 10.1002/pd.4370. Epub 2014 Apr 25.
Second trimester biomarkers were initially introduced with the intent of screening for neural tube defects and then subsequently for Down syndrome. It was soon realized that these markers can be indirect evidence of abnormal placentation and, therefore, can be used for screening for adverse pregnancy outcomes. Several new biomarkers have subsequently been described with conflicting findings regarding their efficiency for screening for adverse pregnancy outcomes. Although a biologically feasible mechanism has been proposed for the role of these biomarkers, they still fall short of an ideal screening test to be clinically useful.
孕中期生物标志物最初是为筛查神经管缺陷而引入的，随后用于筛查唐氏综合征。人们很快意识到，这些标志物可能是胎盘异常的间接证据，因此可用于筛查不良妊娠结局。随后又描述了几种新的生物标志物，但其在筛查不良妊娠结局方面的有效性存在相互矛盾的研究结果。尽管已经提出了这些生物标志物发挥作用的生物学可行机制，但它们仍未达到临床实用的理想筛查测试标准。
